[
  {
    "ts": "2025-11-08T05:57:26+00:00",
    "headline": "Morgan Stanley Raises Merck (MRK) Price Target to $100, Maintains Equal Weight Rating",
    "summary": "Merck & Co., Inc. (NYSE:MRK) is included among the 15 Best DRIP Stocks to Own Right Now. On November 3, Morg⁠an Stanley anal‌yst Tere‍nce Flynn‍ raised the price target for Merck & Co., Inc. (NYSE:MRK) from​ $98​ to $100 while maintaining an Equal Wei⁠g‍ht rating.​ He noted that third⁠-qu⁠arter re‍sults beat‌ exp‌ectations‍, largely due to […]",
    "url": "https://finance.yahoo.com/news/morgan-stanley-raises-merck-mrk-055726208.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "101f03d8-1c15-32d6-b4f1-6e6452fa5232",
      "content": {
        "id": "101f03d8-1c15-32d6-b4f1-6e6452fa5232",
        "contentType": "STORY",
        "title": "Morgan Stanley Raises Merck (MRK) Price Target to $100, Maintains Equal Weight Rating",
        "description": "",
        "summary": "Merck & Co., Inc. (NYSE:MRK) is included among the 15 Best DRIP Stocks to Own Right Now. On November 3, Morg⁠an Stanley anal‌yst Tere‍nce Flynn‍ raised the price target for Merck & Co., Inc. (NYSE:MRK) from​ $98​ to $100 while maintaining an Equal Wei⁠g‍ht rating.​ He noted that third⁠-qu⁠arter re‍sults beat‌ exp‌ectations‍, largely due to […]",
        "pubDate": "2025-11-08T05:57:26Z",
        "displayTime": "2025-11-08T05:57:26Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/28de2ffd72d425beb7bd1a50fc559a22",
          "originalWidth": 1920,
          "originalHeight": 1280,
          "caption": "Morgan Stanley Raises Merck (MRK) Price Target to $100, Maintains Equal Weight Rating",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/xnaTjNI1elXiDbKxXg5RyA--~B/aD0xMjgwO3c9MTkyMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/insidermonkey.com/28de2ffd72d425beb7bd1a50fc559a22.cf.webp",
              "width": 1920,
              "height": 1280,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/p8UswiqXV3Tu7QoCV306Gg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/28de2ffd72d425beb7bd1a50fc559a22.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/morgan-stanley-raises-merck-mrk-055726208.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/morgan-stanley-raises-merck-mrk-055726208.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MRK"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-08T19:30:45+00:00",
    "headline": "Merck Takes On Amgen, Regeneron, Lowering Stubbornly High Cholesterol By 60%",
    "summary": "Merck said Saturday its new pill — a potential rival to Regeneron and Amgen — lowered stubbornly high cholesterol by almost 60%.",
    "url": "https://www.investors.com/news/technology/merck-amgen-regeneron-pcsk9-pill-cholesterol-treatment/?src=A00220&yptr=yahoo",
    "source": "Investor's Business Daily",
    "provider": "yfinance",
    "raw": {
      "id": "77c014c2-bd71-3292-a1eb-46865731ad9b",
      "content": {
        "id": "77c014c2-bd71-3292-a1eb-46865731ad9b",
        "contentType": "STORY",
        "title": "Merck Takes On Amgen, Regeneron, Lowering Stubbornly High Cholesterol By 60%",
        "description": "",
        "summary": "Merck said Saturday its new pill — a potential rival to Regeneron and Amgen — lowered stubbornly high cholesterol by almost 60%.",
        "pubDate": "2025-11-08T19:30:45Z",
        "displayTime": "2025-11-08T19:30:45Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/77c014c2-bd71-3292-a1eb-46865731ad9b/merck-takes-on-amgen-.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/ibd.com/4406f75d0cf53b5ec3699449ce6a95f5",
          "originalWidth": 1000,
          "originalHeight": 563,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/NEZ9RtfqVgQ6FfCbCDSWhQ--~B/aD01NjM7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/ibd.com/4406f75d0cf53b5ec3699449ce6a95f5.cf.webp",
              "width": 1000,
              "height": 563,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/KoBgMmseQwbdIz9Avpeh7Q--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/ibd.com/4406f75d0cf53b5ec3699449ce6a95f5.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Investor's Business Daily",
          "url": "http://www.investors.com/"
        },
        "canonicalUrl": {
          "url": "https://www.investors.com/news/technology/merck-amgen-regeneron-pcsk9-pill-cholesterol-treatment/?src=A00220&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MRK"
            },
            {
              "symbol": "SNY"
            },
            {
              "symbol": "SNYNF"
            },
            {
              "symbol": "REGN"
            },
            {
              "symbol": "AMGN"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-08T19:30:00+00:00",
    "headline": "Merck’s Enlicitide Decanoate, an Investigational Oral PCSK9 Inhibitor, Significantly Reduced LDL-C in Phase 3 CORALreef Lipids Trial",
    "summary": "RAHWAY, N.J., November 08, 2025--Merck’s Enlicitide Decanoate, an Investigational Oral PCSK9 Inhibitor, Significantly Reduced LDL-C in Phase 3 CORALreef Lipids Trial",
    "url": "https://finance.yahoo.com/news/merck-enlicitide-decanoate-investigational-oral-193000145.html",
    "source": "Business Wire",
    "provider": "yfinance",
    "raw": {
      "id": "0cc3c429-ff2a-36ee-932d-0611fd11f220",
      "content": {
        "id": "0cc3c429-ff2a-36ee-932d-0611fd11f220",
        "contentType": "STORY",
        "title": "Merck’s Enlicitide Decanoate, an Investigational Oral PCSK9 Inhibitor, Significantly Reduced LDL-C in Phase 3 CORALreef Lipids Trial",
        "description": "",
        "summary": "RAHWAY, N.J., November 08, 2025--Merck’s Enlicitide Decanoate, an Investigational Oral PCSK9 Inhibitor, Significantly Reduced LDL-C in Phase 3 CORALreef Lipids Trial",
        "pubDate": "2025-11-08T19:30:00Z",
        "displayTime": "2025-11-08T19:30:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/business-wire.com/d2c3b24a71567c8956a799a6c1046c72",
          "originalWidth": 480,
          "originalHeight": 217,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/b4RwyG3jY8lsUVitar3eTA--~B/aD0yMTc7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/d2c3b24a71567c8956a799a6c1046c72.cf.webp",
              "width": 480,
              "height": 217,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/ARKbDdxo366WAHSlhJ1OGw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/d2c3b24a71567c8956a799a6c1046c72.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Business Wire",
          "url": "http://www.businesswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/merck-enlicitide-decanoate-investigational-oral-193000145.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/merck-enlicitide-decanoate-investigational-oral-193000145.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MRK"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-08T22:28:00+00:00",
    "headline": "More Drugs to Fight High Cholesterol Are Emerging",
    "summary": "The lipid-reducing medicines, among the most widely prescribed drugs in the U.S., have been a mainstay of heart-disease prevention and treatment for decades.  Now some patients have other cholesterol-busting medicines available as options—and even more alternatives are on the horizon.  Certain patients already can take a twice-yearly injection, sold by  Novartis  as Leqvio, that uses an RNA-based technology, or a more frequent injection that targets a protein called PCSK9 that interferes with the body’s ability to clear the bad form of cholesterol.",
    "url": "https://www.wsj.com/health/pharma/more-drugs-to-fight-high-cholesterol-are-emerging-3fdef02f?siteid=yhoof2&yptr=yahoo",
    "source": "The Wall Street Journal",
    "provider": "yfinance",
    "raw": {
      "id": "1d4903ec-1ef8-32e2-8d6f-b3be0c767e3b",
      "content": {
        "id": "1d4903ec-1ef8-32e2-8d6f-b3be0c767e3b",
        "contentType": "STORY",
        "title": "More Drugs to Fight High Cholesterol Are Emerging",
        "description": "",
        "summary": "The lipid-reducing medicines, among the most widely prescribed drugs in the U.S., have been a mainstay of heart-disease prevention and treatment for decades.  Now some patients have other cholesterol-busting medicines available as options—and even more alternatives are on the horizon.  Certain patients already can take a twice-yearly injection, sold by  Novartis  as Leqvio, that uses an RNA-based technology, or a more frequent injection that targets a protein called PCSK9 that interferes with the body’s ability to clear the bad form of cholesterol.",
        "pubDate": "2025-11-08T22:28:00Z",
        "displayTime": "2025-11-08T22:28:00Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/1d4903ec-1ef8-32e2-8d6f-b3be0c767e3b/more-drugs-to-fight-high.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/wsj.com/62c3a9b0c0b3c3c0ce761461caf708fa",
          "originalWidth": 1280,
          "originalHeight": 640,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/xRsbfdLF2lhj_ncpD2l0dA--~B/aD02NDA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/wsj.com/62c3a9b0c0b3c3c0ce761461caf708fa.cf.webp",
              "width": 1280,
              "height": 640,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/bR3lqIwavqXgJMzE8g8wUQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/wsj.com/62c3a9b0c0b3c3c0ce761461caf708fa.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "The Wall Street Journal",
          "url": "http://www.wsj.com/"
        },
        "canonicalUrl": {
          "url": "https://www.wsj.com/health/pharma/more-drugs-to-fight-high-cholesterol-are-emerging-3fdef02f?siteid=yhoof2&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NVS"
            },
            {
              "symbol": "NVSEF"
            },
            {
              "symbol": "NTLA"
            },
            {
              "symbol": "CRSP"
            },
            {
              "symbol": "AMGN"
            },
            {
              "symbol": "NOVN.SW"
            },
            {
              "symbol": "MRK"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]